ASCO 2021: Presentations about whole genome sequencing
At the congress of the American Society of Clinical Oncology (ASCO) on 4-8 June 2021 researchers Kris Samsom and Luuk Schipper of the Dutch Cancer Institute (NKI) have presented their findings on whole genome sequencing.
In the poster presentation
Whole Genome Sequencing (WGS) is feasible in routine clinical care
Kris Samsom of the Dutch Cancer Institute explains the results of their research in which they conclude that WGS is feasible in routine diagnostics.
In the poster presentation
Whole Genome Sequencing (WGS) improves sarcoma diagnosis and patient care
Luuk Schipper of the Dutch Cancer Institute explains how they came to the conclusion in their research that WGS can help improve the diagnosis and the treatment of patients with sarcomas.
More information
- Paper in The Journal of Molecular Diagnostics: Clinical validation of Whole Genome Sequencing for cancer diagnostics
- Interview with Kim Monkhorst, patholoog NKI/AvL about the interim results of WIDE: Whole Genome Sequencing feasible in clinical practice
- More information about WGS and the extensive DNA test: OncoAct.nl
All news
Also read
In search of the optimal treatment strategy for glioblastoma
Patients with recurrent glioblastoma have an unfavorable outlook and few treatment options. The recently launched GLOW study should change this …
Single WGS analysis of metastases is sufficient in most cases
DNA analysis of the tumor is of crucial importance to determine treatment options for patients with metastasized lung cancer. But …
SAGE: New algorithm for analysis of tumor DNA reveals mutations previously not found
At Hartwig we “analyse sequenced tumor DNA”. This is something we try to continuously improve. These analyses are shared with …
The knowledge we gather with WGS can bring us a step closer to our goal to find an effective and suitable treatment for every single patient, not based on ‘one size fits all’, but adjusted to the characteristics of the patient and the tumor.